Switch theme
Sign up to access all valuation multiples
Spineguard is engaged in the design and production of medical instruments used for spinal surgeries.
2009
19
LTM Revenue $5.4M
LTM EBITDA -$3.1M
$9.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Spineguard has a last 12-month revenue of $5.4M and a last 12-month EBITDA of -$3.1M.
In the most recent fiscal year, Spineguard achieved revenue of $4.6M and an EBITDA of -$3.8M.
Spineguard expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Spineguard valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $4.6M | $5.0M | XXX | XXX | XXX |
| Gross Profit | $3.9M | $5.1M | XXX | XXX | XXX |
| Gross Margin | 84% | 101% | XXX | XXX | XXX |
| EBITDA | -$3.8M | -$3.4M | XXX | XXX | XXX |
| EBITDA Margin | -81% | -67% | XXX | XXX | XXX |
| Net Profit | -$1.9M | -$2.6M | XXX | XXX | XXX |
| Net Margin | -40% | -51% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Spineguard's stock price is EUR 0 (or $0).
Spineguard has current market cap of EUR 7.1M (or $7.7M), and EV of EUR 8.9M (or $9.6M).
See Spineguard trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.6M | $7.7M | XXX | XXX | XXX | XXX | $-0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Spineguard has market cap of $7.7M and EV of $9.6M.
Spineguard's trades at 1.8x LTM EV/Revenue multiple, and -3.1x LTM EBITDA.
Analysts estimate Spineguard's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Spineguard and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $9.6M | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | -2.9x | XXX | XXX | XXX |
| P/E | -1.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -2.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSpineguard's NTM/LTM revenue growth is 27%
Spineguard's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Spineguard's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Spineguard's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Spineguard and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -67% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -11% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -40% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 42% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 33% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 159% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Spineguard acquired XXX companies to date.
Last acquisition by Spineguard was XXXXXXXX, XXXXX XXXXX XXXXXX . Spineguard acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Spineguard founded? | Spineguard was founded in 2009. |
| Where is Spineguard headquartered? | Spineguard is headquartered in France. |
| How many employees does Spineguard have? | As of today, Spineguard has 19 employees. |
| Is Spineguard publicy listed? | Yes, Spineguard is a public company listed on PAR. |
| What is the stock symbol of Spineguard? | Spineguard trades under ALSGD ticker. |
| When did Spineguard go public? | Spineguard went public in 2013. |
| Who are competitors of Spineguard? | Similar companies to Spineguard include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Spineguard? | Spineguard's current market cap is $7.7M |
| What is the current revenue of Spineguard? | Spineguard's last 12-month revenue is $5.4M. |
| What is the current EBITDA of Spineguard? | Spineguard's last 12-month EBITDA is -$3.1M. |
| What is the current EV/Revenue multiple of Spineguard? | Current revenue multiple of Spineguard is 1.8x. |
| What is the current EV/EBITDA multiple of Spineguard? | Current EBITDA multiple of Spineguard is -3.1x. |
| What is the current revenue growth of Spineguard? | Spineguard revenue growth between 2023 and 2024 was 8%. |
| Is Spineguard profitable? | Yes, Spineguard is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
